

AGENDA

7:30am NETWORKING BREAKFAST

8:00am WELCOME & TCF-001 TRACK OVERVIEW

Jim Palma, Executive Director, *TargetCancer Foundation*

8:30am PATIENT KEYNOTE

Allen Chankowsky, Author, *"On the Other Side of Terminal"*

8:50am SCIENTIFIC KEYNOTE

Precision Genomics and Immunotherapy for Rare Cancers: The N-of-1 Era
Razelle Kurzrock, MD, *Medical College of Wisconsin*

9:25am SESSION 1: CLINICAL TRIALS

Tumor Agnostic Therapies and Clinical Trials for Rare Cancers
Vivek Subbiah, MD, *MD Anderson Cancer Center*

9:55am MORNING BREAK

10:10am MOLECULAR TUMOR BOARD

TCF-001 TRACK Molecular Tumor Board

10:50am SESSION 2: GERMLINE AND SOMATIC GENETICS

Genetic Counseling and Testing in Rare Cancers
Catherine Skefos, MA, MS, CGC, *MD Anderson Cancer Center*

Somatic Genetics and Molecular Testing
Julia Elvin, MD, PhD, *Foundation Medicine*

Rare Cancer Types: Discovery of Novel Genetics
Jorge Reis-Filho, MD, PhD, *Memorial Sloan Kettering Cancer Center*

12:30pm NETWORKING LUNCH

AGENDA

- 1:20pm** **SESSION 3: BIOMARKERS AND EMERGING TECHNOLOGIES**
AI-Driven Computational Pathology
Faisal Mahmood, PhD, *Brigham and Women's Hospital*
Epigenomic Technologies to Study Rare Cancers
Miguel Rivera, MD, *Massachusetts General Hospital*
Biomarker Driven Early Intervention: PD-1 Blockade as Curative-Intent Therapy
in Locally Advanced Mismatch Repair Deficient Rectal Cancer
Andrea Cercek, MD, *Memorial Sloan Kettering Cancer Center*
- 3:00pm** **SESSION 4: PATIENT DRIVEN DATA DISCOVERY**
The Angiosarcoma Project Story
Corrie Painter, PhD, *Broad Institute of MIT and Harvard*
- 3:30pm** **SESSION 5: PANEL AND GUIDED DISCUSSION**
Challenges and barriers to adoption of biomarker testing
Jennifer Levin Carter, MD, MPH, *Sandbox Industries, The Blue Venture Fund*
Deborah Morosini, MD, *Honey Locust Advisers LLC*
Susan Spinosa, *NTRKers*

THANK YOU TO OUR SPONSORS

